**Name of Journal: *World Journal of Methodology***

**Manuscript NO: 33284**

**Manuscript Type: Review**

**Targeted temperature management in neurological intensive care unit**

Muengtaweepongsa S *et al.* Targeted temperature management in neurological ICU

**Sombat Muengtaweepongsa, Winchana Srivilaithon**

**Sombat Muengtaweepongsa,** Division of Neurology, Department of Medicine, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand

**Winchana Srivilaithon,** Department of Emergency Medicine, Thammasat University Hospital, Pathum Thani 12120, Thailand

**Author contributions:** Muengtaweepongsa S contributed to conception and design of the work, data collection, drafing the article, critical revision of the article, final approval; Srivilaithon W contributed to data collection, drafing the article.

**Conflict-of-interest statement:** No conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Sombat Muengtaweepongsa, MD,** Division of Neurology, Department of Medicine, Faculty of Medicine, Thammasat University, Rangsit Campus, Patholyothin Rd., Pathum Thani 12120, Thailand. musombat@tu.ac.th

**Telephone:** +66-29-269794

**Fax:** +66-29-269793

**Received:** January 30, 2017

**Peer-review started:** February 12, 2017

**First decision:** March 28, 2017

**Revised:** April 12, 2017

**Accepted:** May 18, 2017

**Article in press:**

**Published online:**

**Abstract**

Targeted temperature management (TTM) shows the most promising Neuroprotective Therapy against hypoxic/ischemic encephalopathy (HIE). In addition, TTM is also useful for treatment of elevated intracranial pressure (ICP). HIE and elevated ICP are common catastrophic conditions in patients admitted in Neurologic intensive care unit (ICU). The most common cause of HIE is cardiac arrest. Randomized control trials demonstrate clinical benefits of TTM in patients with post-cardiac arrest. Although clinical benefit of ICP control by TTM in some specific critical condition, for an example in traumatic brain injury, is still controversial, efficacy of ICP control by TTM is confirmed by both in vivo and in vitro studies. Several methods of TTM have been reported in the literature. TTM can apply to various clinical conditions associated with hypoxic/ischemic brain injury and elevated ICP in Neurologic ICU.

**Key words:** Targeted temperature management; Neuroprotective therapy; Ischemic/hypoxic encephalopathy; Intracranial pressure; Surface cooling; Endovascular cooling

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Two main purposes of targeted temperature management (TTM) in patients admitted in neurological intensive care unit are neuroprotective therapy and intracranial pressure (ICP) control. TTM is the most potent neuroprotective treatment due to its numerous methods of protection against ischemic/hypoxic injury. TTM provides capable ICP reductive action. Two most popular methods using in clinical practice and clinical trials are invasive endovascular technique and non-invasive surface cooling. Fast induction, smooth maintenance and slow rewarming are the important steps to achieve ideal TTM.

Muengtaweepongsa S, Srivilaithon W. Targeted temperature management in neurological intensive care unit. *World J Methodol* 2017; In press

**INTRODUCTION**

Clinical benefit of therapeutic hypothermia in patients with post-cardiac arrest syndrome (PCAS) has been demonstrated by two randomized control trials since 2002[1,2]. However, the term ″therapeutic hypothermia″ has been replaced with ″targeted temperature management (TTM)″ since 2011 after the meeting of five major professional physician societies[3]. TTM defines as a type of treatment that reduces a subject's core temperature until a specific target with the purpose in salvage or alleviate the [tissue](http://en.wikipedia.org/wiki/Tissue_(biology)) injury from deficiency of blood perfusion[4]. TTM is recognized as a only established neuroprotective therapy for hypoxic/ischemic brain injury, particularly in patients after cardiac arrest[5]. The clinical practice guidelines state that TTM should apply as a major treatment for patients following successful resuscitation from cardiac arrest[6-10].

Elevated intracranial pressure (ICP) is one of the common conditions found in patients admitted in neurologic intensive care unit (ICU)[11]. Many clinical and animal trials demonstrate that TTM effectively lowers ICP[12]. However, the application of TTM as ICP control in each particular disease, for examples in primary intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), traumatic brain injury (TBI) and cerebral infarct, needs to be proved by large randomized controlled trial[13].

**HYPOXIC/ISCHEMIC CASCADE**

Hypoxic/ischemic brain damage is associated with the abruption of cerebral blood flow (CBF)[14]. Cessation of brain circulation leads to compound neurologic damages, the so-called hypoxic/ischemic cascade[15]. After the deficiency of oxygen and circulation supplying occur, adenosine triphosphate ([ATP](http://en.wikipedia.org/wiki/Adenosine_triphosphate)) manufacturing malfunction develops[16]. Neurons and glials change from aerobic to [anaerobic process](http://en.wikipedia.org/wiki/Fermentation_(biochemistry)), resulting in accumulation of [lactic acid](http://en.wikipedia.org/wiki/Lactic_acid)s[17]. Cells become depolarized due to the sodium-potassium ATPase pumps failure, letting [ions](http://en.wikipedia.org/wiki/Ion), particularly [calcium](http://en.wikipedia.org/wiki/Calcium) (Ca++), to invade themselves[18]. Elevated intracellular Ca++ stimulates the release of the well-known excitatory [amino acid](http://en.wikipedia.org/wiki/Amino_acid) [neurotransmitter](http://en.wikipedia.org/wiki/Neurotransmitter) such as [glutamate](http://en.wikipedia.org/wiki/Glutamate)[19]. Glutamate permits further Ca++ influx the cells by activate the opening of Calcium-permeable [NMDA receptors](http://en.wikipedia.org/wiki/NMDA_receptor) and [AMPA receptors](http://en.wikipedia.org/wiki/AMPA_receptor)[20]. After excessive calcium Ca++ influx, the production of deleterious substances including various [free radicals](http://en.wikipedia.org/wiki/Free_radical), [reactive oxygen species](http://en.wikipedia.org/wiki/Reactive_oxygen_species), [phospholipases](http://en.wikipedia.org/wiki/Phospholipase), [ATPases](http://en.wikipedia.org/wiki/atpase), and [endonucleases](http://en.wikipedia.org/wiki/Endonuclease), the so-called excitotoxicity materials, initiates[21]. Membrane and mitochondria break down and lead to development of necrotic cells and apoptosis. Glutamate and other harmful materials are then released from these necrotic cells into the environment[22]. These materials cause further damage to adjacent cells. This continuous injury, the so-called [reperfusion damage](http://en.wikipedia.org/wiki/Reperfusion_injury), usually starts when the cerebral tissue gets reperfused[23]. Inflammatory scavengers get accumulated to eat up the debris tissue and then generate many cytokines[24]. These toxic materials disrupt the [blood-brain barrier](http://en.wikipedia.org/wiki/Blood%2525E2%252580%252593brain_barrier) (BBB). Destroyed BBB conducts to leakage of huge protein molecules particularly albumins into the environment causing brain edema[25]. Brain edema produces pressure effect of and further harm to adjacent brain tissue[26]. The hypoxic/ischemic cascade are shown in Figure 1.

**ICP**

The theory of ICP, the so-called Monro-Kellie doctrine, was first postulated by Alexander Monro in 1783 before George Kellie published the article support Monro’s idea in 1824[27,28]. This theory states that since the skull is a permanent volume and the brain is enclosed by rigid meninges, therefore, alterations in the volume of the intracranial components will affect ICP[29]. The intracranial components include blood, cerebrospinal fluid (CSF), and brain tissue, all of which are relatively constant. An enlargement in one component or development of a mass lesion will elevate ICP and require a diminishing in another component in order to preserve the permanent intracranial volume[30]. An expanding lesion can initially shift CSF and blood out of the cranium without much change in ICP. However, this capacity to compensate for changes in volume has limitation. If the lesion continues expansion, ICP will get elevated[31]. Elevated ICP leads to cerebral herniation[32]. Moreover, increased ICP harms CBF by depressed cerebral perfusion pressure (CPP), where CPP is calculated by subtraction of ICP from mean arterial pressure (MAP)[33].

**MECHANISMS OF TTM**

The multiple sites of actions are thought to be the protective effects of TTM on ischemic cascade[34]. These multiple sites of actions include prevention of BBB disruption, reduction of oxygen derivative free radical release, reduction of excitotoxic neurotransmitter production, anti-inflammatory action and delayed apoptosis[35]. The major neuroprotective effect of TTM in patients after cardiac arrest with restored of systemic circulation (ROSC) is apparently the protective effect on reperfusion damage[36]. Numerous effects resulted from reperfusion damage, including oxygen free radical production, excitotoxic neurotransmitter release, and calcium influx, are all diminished by TTM[5,6,34]. Moreover, TTM also reduces cerebral metabolic rate, protects mitochondrial break down and prevents cell membrane leakage[37,38]. The neurons and glials are finally prevented to turn apoptosis[38]. Protection of BBB damage is an important action of TTM[39]. Diminution of BBB disruption helps to reduce brain edema then lower ICP[38]. Effectiveness of ICP reduction by TTM in various brain disorders has been demonstrated in many clinical and experimental studies[12,40-43]. However, absolute profit of ICP control by TTM in diverse clinical features needs to be confirmed with large scale RCTs[3,13].

**THE IDEAL TTM**

The course of TTM is divided into three phases[44]. The beginning of TTM is known as induction phase. The main idea of induction phase is to lower the current core temperature to the target as fast as possible[45,46]. Subsequently, that target temperature is smoothly maintained for certain duration (usually for 24 h), the so-called maintenance or sustainment phase[45,46]. The last part, the so-called rewarming phase, the core temperature is slowly raised to the ordinary point with actively control rate, usually at 0.2-0.5 degree Celsius per hour[45,46]. Most of the important complications, particularly infection, usually happen during this last phase when the temperature is passively rewarmed with too rapid and out-of-control rate[4]. The ideal temperature curve of a patient with cardiac arrest treated with TTM is showed in Figure 2.

**METHODS TO ACHIEVE IDEAL TTM**

Many methods of TTM have been reported in the literature**.** Some methods are no longer utilized in clinical practice any more due to their unfeasibility or their ineffectiveness. The method with antipyretic drugs alone are, of course, not sufficient to achieve ideal TTM[47]. Under lack of electricity source circumstance, intravenous cold crystalloid solution may be helpful for initiation of TTM during pre-hospital period[48,49]. However, large volume is needed for induction phase. It is still not possible to achieve ideal TTM with intravenous cool fluid alone. Cooling helmets or hoods is effective to achieve selective cerebral TTM in infants however it seems to be ineffective in adults[6,50]. The two most accepted methods in clinical practice and major clinical trials are non-invasive surface technique and invasive endovascular technique[51,52].

***Invasive endovascular methods***

The hallmark of invasive endovascular techniques is central venous catheter with extracorporeal cooling machine[4]. The central venous catheter can be sticked *via* femoral, jugular or subclavian vein. Of course, the auto-feedback temperature regulated system is integrated with the machine. Two commercial brands are obtainable in universal market: CoolGard 3000® and Celcius Control System®. The advantage of endovascular system is effective performance including rapid temperature reduction to the target, smoothly sustainment of target temperature and rewarm with actively controlled rate[53,54]. Application of non-pharmacologic shivering control with skin counter-warming is much convenient and more effective during endovascular cooling[55]. Without sedative effect from pharmacologic shivering control, intubation for airway protection can be avoided under skin counter-warming[56]. That’s why endovascular method is the recommend technique in several studies of TTM in subjects with acute ischemic stroke[57-59]. However, catheter-related complications and limitation of central venous access are disadvantage issues for endovascular method[51,60].

***Non-invasive surface methods***

Compression of ice packs to neck, axilla and groin is the simplest way for surface cooling. Two landmark randomized-controlled-trials (RCT) for TTM in patients with post-cardiac arrest (PCAS) demonstrated effectiveness of this ice packs application[1,2]. However, disadvantage of this technique is awkward, required strenuous staff effort, unreliable temperature control and high risk for complications[61]. The auto-feedback temperature regulated machine provides reliable temperature management and is favorable to perform in clinical practice[47]. The machine comes with circulatory cold water blankets/pads or cold air-flow blankets. Several trademarks of machine are commercially distributed in the worldwide market, including ArcticSun®, CritiCool® andBlanketrol®. The effective automatic cooling system with temperature feedback of the machine helps rapidly lower the temperature to the target and supports slowly rewarm back to the normal baseline temperature. Core temperature monitoring straight connected to the machine is the key for auto-feedback temperature regulated system. The temperature of water within the blankets or pads is automatically regulated by the machine upon target temperature setting and feedback data from core temperature measurement[52]. The surface method with cold water pads is showed in Figure 3.

EMCOOL® pads consist of graphite elements, the high heat conductivity, for cooling media which apply right to the superficial skin. This pads have to get frozen up in ordinary freezer to become 9 degree Celsius before application however do not require power supply while using[62]. Consequently, this system is extremely practical in pre-hospital situation for TTM induction[63].

The novel esophageal cooling device, the most recent non-invasive method, shows preliminary benefit of its use in PCAS patients[64]. The United States Food and Drug Administration (USFDA) has already approved this device[65].

**SHIVERING AND COMMON PHYSIOLOGIC RESPONSE**

Peripheral vasoconstriction is the initial physiologic response when temperature begins to go down[66]. When temperature declines to the certain point, shivering usually occurs[4]. Occurrence of shivering may represent intact physiologic response and indicate good neurologic outcomes[67]. Wonderful shivering control is a key of success to achieve ideal TTM and should be included in the treatment protocol[55,68]. Shivering is usually monitored with the Bedside Shivering Assessment Score during TTM (Table 1)[69]. Elevated peripheral vascular resistance during induction phase of TTM is usually transient and takes no effect to systemic blood pressure[70]. Sinus bradycardia with heart rate less than 50 beats per minute occurs in almost 50%of patients with PCAS during maintenance phase[71]. Nevertheless, this bradycardia should also indicate an intact physiologic response, does not require any treatment due to no hemodynamic effect and may predict good prognosis[72]. Platelets dysfunction and coagulation defect are hematologic abnormalities associated with hypothermia found in non-human experimental models[4,66]. However, abnormal bleeding associated with TTM is infrequently found in real world clinical practice[3,73]. Hypothermia also obliges kidneys to excrete water leading to volume reduction[74]. Serum potassium becomes lower during maintenance phase due to intracellular shift and renal loss however it is expected to be elevated once temperature goes up in rewarming period[4]. Serum amylase becomes elevated when temperature declines, nonetheless, this high serum amylase does not cause pathologic pancreatitis at all[75]. Although elevated blood sugar due to lower insulin level usually occurs during maintenance phase, supplementary insulin may worsen the pre-existing hypokalemia[76]. Infection, particularly pneumonia and sepsis, is a well-known adverse event in patients treated with TTM, however it is usually not associated with unfavorable outcomes[47,77].

**APPLICATION OF TTM IN VARIOUS CLINICAL ENTITIES**

***TTM in PCAS***

Combination of complex pathophysiologic process after resuscitated from cardiac arrest, known as PCAS, attribute to multiple organs damage[78]. Global ischemic cascade occurs in the brain due to generalized and severe ischemia during cardiac arrest along with reperfusion process after return of spontaneous circulation (ROSC) leading to hypoxic/ischemic brain injury[79-81]. This global brain damage is responsible for a major cause of mortality in patients with PCAS pertaining to 68% of out-of hospital cardiac arrest (OHCA) and 23% of in-hospital cardiac arrest (IHCA)[82]. TTM is a well-known neuroprotective therapy for ischemic/hypoxic brain injury[83-85].

Two landmark (RCT show that induced mild hypothermia can reduce mortality rate and improve neurologic outcome in adult patients who remained comatose after resuscitated from out-of hospital cardiac arrest and had ventricular fibrillation (VF) or ventricular tachycardia (VT) as initial cardiac rhythm[1,2]. The benefit from these two RCTs is excellent with number-needed-to-treat (NNT) 7 for avoidance of mortality and NNT 6 for favorable neurological/clinical outcomes[86]. The summary of the two landmark RCTs is revealed in Table 2. Base on the results from these two RCTs, International Liaison Committee on Resuscitation and American Heart Association declared, in 2003 and 2010 respectively, that unconscious adults who become ROSC following OHCA with VT/VF or shockable rhythm should be treated with TTM under target temperature between 32 °C and 34 °C for 12 to 24 h[6,7].

The appropriate target temperature for TTM in adult patients with PCAS then becomes an important dilemma. TTM Trial is a landmark RCT for comparing benefit of TTM in adult patients after OHCA with any initial rhythm at 33 °C *vs* 36 °C[87]. In November 2013, TTM Trial concludes the same benefit of neurologic outcomes and survival at six months in adult patients with OHCA treated with TTM at 33 °C versus which of 36 °C[88]. Furthermore, at six months after discharge from the hospital, survivals in 33 °C and 36 °C group have similarly good quality of life and same level of cognitive function[89].

Clinical profit of TTM in patients with PCAS from other etiologies except OHCA with shockable rhythm remains not well-established[90]. Some small clinical trials report evidence of marginal outcomes benefit in OHCA subgroup with asystole/pulseless electrical activity (PEA), the so-called non-shockable rhythm, and also in IHCA subgroup[6,7,90]. For patients after OHCA with non-shockable rhythm, few observational studies show no difference in neurologic outcomes with TTM but possible reduction of mortality at six months[2,91,92]. A recent observational study included more than 90% of adult patients with non-shockable rhythm show improvement of neurologic outcomes and better survival to hospital discharge with TTM[73]. For patients with IHCA, few observational studies show marginal benefit of TTM in both neurologic outcomes and survival[73,93]. The most update recommendation declared by International Liaison Committee on Resuscitation, American Heart Association and European Resuscitation Council similarly state in 2015 that unconscious adult patients with ROSC after either OHCA or IHCA with either shockable or non-shockable rhythm should be treated with TTM at 32 °C to 36 °C for at least 24 h[8-10]. From the recent meta-analysis, TTM confers to better neurological outcomes than no temperature management in adult patients with PCAS, however, TTM in specific subgroup including initial non-shockable rhythm, IHCA and non-cardiac causes of arrest does not have sufficient data to make any conclusion[94]. The inclusion and exclusion criteria for TTM in adult patients with PCAS at Thammasat University Hospital are showed in Table 3.

Therapeutic Hypothermia after Paediatric Cardiac Arrest (THAPCA) Trial is a landmark study for TTM in all aspects of pediatric patients with PCAS[95]. The results from THAPCA trial demonstrated that TTM with target temperature of 33 °C in pediatric patients with PCAS due to either OHCA or IHCA did not show any outcomes benefit as compared with which of target temperature of 36.8 °C[96,97].

***TTM in ischemic stroke***

In non-human experimental models with on focal brain ischemia, TTM demonstrates a very capable neuroprotective outcomes[98]. However, application of TTM in patients with ischemic stroke still has a lot of limitations[99]. Invasive endovascular method is preferred to apply in patients with acute ischemic stroke due to its feasibility and safety as reported by most clinical studies[56,100]. Under endovascular method, shivering control is convenient with non-pharmacologic skin counter-warming technique[55]. For this reason, pharmacologic anti-shivering technique which usually associated with sedative effect can be avoided[54,100]. Endovascular method is apparently not associated with bleeding complications even in post-thrombolytic condition[100]. Unfortunately, the RCT of TTM with endovascular method at 33 °C following intravenous recombinant plasminogen activator (rtPA) in patients with ischemic stroke (ICTuS 2 Trial) is early stopped due to the approval of interventional thrombectomy and lack of funding[101]. The sample size of ICTus 2 Trial is too small to make any conclusion on efficacy or clinical outcomes of the treatment[101].

With its reperfusion protective action, TTM should be useful to decrease symptomatic intracerebral hemorrhage (sICH) after intravenous rtPA as well as after endovascular treatment[102,103]. The landmark RCT of TTM as neuroprotective treatment with target temperature at 34 °C to 35 °C in patients with acute ischemic stroke (EuroHYP-1) is still ongoing[104]. At this moment, routine application of TTM in patients with acute ischemic stroke is not recommended[105].

Fever control with TTM technique, to keep target temperature less than 37.5 °C, is helpful for patients with acute ischemic stroke[106]. Reduction of ICP with TTM in malignant brain infarct is demonstrated in both experimental and clinical studies[40,42,107]. TTM is helpful for ICP reduction in patients with large middle cerebral artery (MCA) infarct[40]. However, routine application of TTM as ICP reduction in any type of malignant brain infarct is controversial due to insufficient support clinical data of its benefit[3,106].

***TTM in TBI***

Pertaining to experimental animal models for TBI, TTM provides excellent mechanism of action in both Neuroprotection and ICP reduction[108-110]. Two clinical trials in patients with severe TBI from China demonstrated good effect of TTM on ICP control with favorable outcomes after six months to one year[111,112]. Unfortunately, the following meta-analysis, which includes small to medium scale RCTs before 2003, did not demonstrate any benefit to apply TTM as neuroprotective therapy in patients with TBI[113-115]. Finally, two landmark RCTs of TTM as neuroprotective therapy in either adults or children with TBI fail to demonstrate any beneficial outcomes[70,116,117]. Elevated ICP in patients with TBI is common and associated with poor outcomes[118,119]. The previous TTM trials begin rewarming when the peak of elevated ICP occurs at around 48 hours after onset of TBI leading to clinical deterioration[120]. This rebound elevated ICP found during rewarming phase is assumed to be one of the key reasons of failure in previous landmark RCT[121]. Specific group of elevated ICP in patients with TBI may get clinical profit from ICP reduction with TTM[12]. Clinical trial of TTM according to high ICP in patients with TBI was proposed[122]. Unfortunately, large scale RCT of TTM in specific TBI patients with high ICP more than 20 mmHg (Eurotherm3235 Trial) does not demonstrate any clinical benefit[123]. Recent meta-analysis of TTM versus normothermia in adult patients with TBI does not demonstrate any clinical benefit of TTM but reveal risk of developing pneumonia and cardiovascular complications associated with TTM[124]. Large scale RCT of TTM in particular aspects of patients with TBI is still ongoing[125]. At this moment, ordinary application of TTM in patients with TBI without clinical study is not recommended[126].

***Fever controls in neurological ICU with TTM machine***

Fever is commonly found in patients admitted in Neurological ICU, increases risk of complications, and is usually associated with unfavorable clinical outcomes[127,128]. For example, in patients with ischemic stroke, chance to develop poor outcomes increases 2.2 times in each one degree exceeding 37°C when compared with patients who have normal temperature[129]. Most common cause of fever in Neurological ICU is infection[130]. Similar method of TTM can be applied for fever control in Neurological ICU[131,132]. The commonly use techniques such as surface and endovascular are convenient and save to employ for fever control[131,132]. Fever control in patients with septic shock with external TTM machine reduces early mortality[133]. However, overall benefit of antipyretic therapy with external TTM in patients with sepsis is still not approved[134,135]. Fever control in patients with acute ischemic stroke is recommended per standard guidelines[105].

***TTM in other clinical entities***

TTM can apply as organ protective therapy from ischemic effect during cardiovascular surgery with circulatory arrest[136,137]. The landmark RCT of TTM for the period of operation in patients with benign grade subarachnoid hemorrhage (SAH) from ruptured intracranial aneurysm (World Federation of Neurological Surgeons scale between one and three) did not show any clinical benefit with more frequent associated infection[138]. TTM can reduce perilesional edema with favorable outcomes in animal models with intracerebral hemorrhage (ICH)[139]. The TTM after intracerebral hemorrhage (TTM-ICH) trial is ongoing[140]. At this moment, routine use of TTM in patients with ICH is not recommended[141]. The prospective protocol-selected trial demonstrated potential clinical benefit of local TTM in patients with neurologically complete spinal cord injury[142]. Experts recommend that TTM can be the option for ICP control in patients with fulminant hepatic encephalopathy particularly while waiting for liver transplantation[143].

Application of TTM in donors demonstrates organ protective effect on kidney in recipients[144]. This RCT is the first ever for clinical trial which demonstrates organ defensive action of TTM from hypoxic/ischemic cascade outside the brain. The process of TTM at 34 °C-35 °C in kidney donors in this study is convenient and the cost of treatment is economic[145]. TTM in kidney donors can be its second class I recommendation per standard guidelines following post-cardiac arrest in the near future.

**CONCLUSION**

Two main purposes of TTM in patients admitted in Neurological ICU are neuroprotective therapy and ICP control. TTM is the most potent neuroprotective treatment due to its numerous effects against ischemic/hypoxic injury. TTM provides reliable ICP reductive action. Two most popular methods of TTM using in clinical practice and clinical trials are invasive endovascular technique and non-invasive surface cooling. Fast induction, smooth maintenance and slow rewarming are the important steps to achieve ideal TTM. The strongest clinical benefit of TTM is the excellent outcomes with neuroprotective effect in patients with PCAS. TTM has been recommended as the essential treatment for OHCA with shockable rhythm for more than 10 years. Even with marginal benefit, TTM is still recommended for non-shockable rhythm and IHCA subgroup. TTM may give benefit in patients with acute ischemic stroke however its role needs to be proved with large scale RCT. TTM should be clinically useful for ICP reduction in patients with malignant MCA infarct. Routine use of TTM in patients with TBI as neuroprotective therapy or ICP control is still not recommended due to lacking of any benefit from many RCTs. TTM machine can be applied as fever control in patients with various conditions in Neurological ICU. Fever control should help to improve clinical outcomes in patients admitted in Neurological ICU.

**ACKNOWLEDGEMENTS**

The authors acknowledgement the National Research University Project of Thailand from Office of Higher Education Commission and Center of Excellence in Integrated Sciences for Holistic Stroke Research from Thammasat University.

**REFERENCES**

1 **Hypothermia after Cardiac Arrest Study G**. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. *N Engl J Med* 2002; **346**: 549-556 [PMID: 11856793 DOI: 10.1056/NEJMoa012689]

2 **Bernard SA**, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med* 2002; **346**: 557-563 [PMID: 11856794 DOI: 10.1056/NEJMoa003289]

3 **Nunnally ME**, Jaeschke R, Bellingan GJ, Lacroix J, Mourvillier B, Rodriguez-Vega GM, Rubertsson S, Vassilakopoulos T, Weinert C, Zanotti-Cavazzoni S, Buchman TG. Targeted temperature management in critical care: a report and recommendations from five professional societies. *Crit Care Med* 2011; **39**: 1113-1125 [PMID: 21187745 DOI: 10.1097/CCM.0b013e318206bab2]

4 **Mayer SA**, Sessler DI. Therapeutic hypothermia. In: Mayer SA, Claassen J, editors. Prevention and Treatment of Fever in Neurocritical Care. New York, 2005: 629

5 **Polderman KH**. Application of therapeutic hypothermia in the ICU: opportunities and pitfalls of a promising treatment modality. Part 1: Indications and evidence. *Intensive Care Med* 2004; **30**: 556-575 [PMID: 14767591 DOI: 10.1007/s00134-003-2152-x]

6 **Nolan JP**, Morley PT, Vanden Hoek TL, Hickey RW, Kloeck WG, Billi J, Böttiger BW, Morley PT, Nolan JP, Okada K, Reyes C, Shuster M, Steen PA, Weil MH, Wenzel V, Hickey RW, Carli P, Vanden Hoek TL, Atkins D. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. *Circulation* 2003; **108**: 118-121 [PMID: 12847056 DOI: 10.1161/01.CIR.0000079019.02601.90]

7 **Peberdy MA**, Callaway CW, Neumar RW, Geocadin RG, Zimmerman JL, Donnino M, Gabrielli A, Silvers SM, Zaritsky AL, Merchant R, Vanden Hoek TL, Kronick SL. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 2010; **122**: S768-S786 [PMID: 20956225]

8 **Callaway CW**, Donnino MW, Fink EL, Geocadin RG, Golan E, Kern KB, Leary M, Meurer WJ, Peberdy MA, Thompson TM, Zimmerman JL. Part 8: Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 2015; **132**: S465-S482 [PMID: 26472996 DOI: 10.1161/CIR.0000000000000262]

9 **Nolan JP**, Soar J, Cariou A, Cronberg T, Moulaert VR, Deakin CD, Bottiger BW, Friberg H, Sunde K, Sandroni C. European Resuscitation Council and European Society of Intensive Care Medicine 2015 guidelines for post-resuscitation care. *Intensive Care Med* 2015; **41**: 2039-2056 [PMID: 26464394 DOI: 10.1007/s00134-015-4051-3]

10 **Hazinski MF**, Nolan JP, Aickin R, Bhanji F, Billi JE, Callaway CW, Castren M, de Caen AR, Ferrer JM, Finn JC, Gent LM, Griffin RE, Iverson S, Lang E, Lim SH, Maconochie IK, Montgomery WH, Morley PT, Nadkarni VM, Neumar RW, Nikolaou NI, Perkins GD, Perlman JM, Singletary EM, Soar J, Travers AH, Welsford M, Wyllie J, Zideman DA. Part 1: Executive Summary: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation* 2015; **132**: S2-39 [PMID: 26472854 DOI: 10.1161/CIR.0000000000000270]

11 **Kurtz P**, Fitts V, Sumer Z, Jalon H, Cooke J, Kvetan V, Mayer SA. How does care differ for neurological patients admitted to a neurocritical care unit versus a general ICU? *Neurocrit Care* 2011; **15**: 477-480 [PMID: 21519958 DOI: 10.1007/s12028-011-9539-2]

12 **Sadaka F**, Veremakis C. Therapeutic hypothermia for the management of intracranial hypertension in severe traumatic brain injury: a systematic review. *Brain Inj* 2012; **26**: 899-908 [PMID: 22448655 DOI: 10.3109/02699052.2012.661120]

13 **Corry JJ**. The use of targeted temperature management for elevated intracranial pressure. *Curr Neurol Neurosci Rep* 2014; **14**: 453 [PMID: 24740807 DOI: 10.1007/s11910-014-0453-9]

14 **Muengtaweepongsa S**. Methods and clinical applications of targeted temperature management. *Neurology Asia* 2015; **20**: 325-333

15 **Gusev EISVI**. Brain ischemia. New York: Kluwer Academic/Plenum Publishers, 2003

16 **Zhao H**, Kilgas S, Alam A, Eguchi S, Ma D. The Role of Extracellular Adenosine Triphosphate in Ischemic Organ Injury. *Crit Care Med* 2016; **44**: 1000-1012 [PMID: 26825859 DOI: 10.1097/CCM.0000000000001603]

17 **Xing C**, Arai K, Lo EH, Hommel M. Pathophysiologic cascades in ischemic stroke. *Int J Stroke* 2012; **7**: 378-385 [PMID: 22712739 DOI: 10.1111/j.1747-4949.2012.00839.x]

18 **Stead SM**, Daube JR. Basics of Neurophysiology. *Clinical Neurophysiology* 2016: 3

19 **Hinkle JL**, Bowman L. Neuroprotection for ischemic stroke. *J Neurosci Nurs* 2003; **35**: 114-118 [PMID: 12795039]

20 **Bennett MV**, Pellegrini-Giampietro D, Gorter J, Aronica E, Connor J, Zukin RS. The GluR2 hypothesis: Ca -permeable AMPA receptors in delayed neurodegeneration. Proceedings of the Cold Spring Harbor symposia on quantitative biology. Cold Spring Harbor Laboratory Press, 1996: 373-384

21 **Labiche LA**, Grotta JC. Clinical trials for cytoprotection in stroke. *NeuroRx* 2004; **1**: 46-70 [PMID: 15717007 DOI: 10.1602/neurorx.1.1.46]

22 **Hazell AS**. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. *Neurochem Int* 2007; **50**: 941-953 [PMID: 17576023 DOI: 10.1016/j.neuint.2007.04.026]

23 **Aronowski J**, Strong R, Grotta JC. Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. *J Cereb Blood Flow Metab* 1997; **17**: 1048-1056 [PMID: 9346429 DOI: 10.1097/00004647-199710000-00006]

24 **Iadecola C**, Anrather J. The immunology of stroke: from mechanisms to translation. *Nat Med* 2011; **17**: 796-808 [PMID: 21738161 DOI: 10.1038/nm.2399]

25 **Xi G**, Keep RF, Hoff JT. Pathophysiology of brain edema formation. *Neurosurg Clin N Am* 2002; **13**: 371-383 [PMID: 12486926]

26 **Strbian D**, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E, Abo-Ramadan U, Tatlisumak T. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. *Neuroscience* 2008; **153**: 175-181 [PMID: 18367342 DOI: 10.1016/j.neuroscience.2008.02.012]

27 **Monro A**. Observations on the structure and function of the nervous system. Edinburgh: Creech & Johnson, 1783

28 **Kelly G**. Appearances observed in the dissection of two individuals; death from cold and congestion of the brain. *Trans Med Chir Sci Edinb* 1824: 84-169

29 **Neff S**, Subramaniam RP. Monro-Kellie doctrine. *J Neurosurg* 1996; **85**: 1195 [PMID: 8929522]

30 **Mokri B**. The Monro-Kellie hypothesis: applications in CSF volume depletion. *Neurology* 2001; **56**: 1746-1748 [PMID: 11425944]

31 **Kincaid MS**, Lam AM. Monitoring and managing intracranial pressure. *Continuum* 2006; **12**: 16 [DOI: 10.1212/01.con.0000290439.87946.ed]

32 **Sheth K**, McCullough M, Kazmi S, Lazaridis C, O'Phelan K, Shepherd SA, DeJesus-Alvelo I, Marshall SA, Willis AM, Durrant JC. Cerebral Herniation Syndromes and Intracranial Hypertension: Rutgers University Press, 2016

33 **Villa F**, Citerio G. Intracranial pressure monitoring. Oxford Textbook of Neurocritical Care, 2016: 107 [DOI: 10.1093/med/9780198739555.003.0009]

34 **Polderman KH**. Mechanisms of action, physiological effects, and complications of hypothermia. *Crit Care Med* 2009; **37**: S186-S202 [PMID: 19535947 DOI: 10.1097/CCM.0b013e3181aa5241]

35 **Talma N**, Kok WF, de Veij Mestdagh CF, Shanbhag NC, Bouma HR, Henning RH. Neuroprotective hypothermia - Why keep your head cool during ischemia and reperfusion. *Biochim Biophys Acta* 2016; **1860**: 2521-2528 [PMID: 27475000 DOI: 10.1016/j.bbagen.2016.07.024]

36 **Madathil RJ**, Hira RS, Stoeckl M, Sterz F, Elrod JB, Nichol G. Ischemia reperfusion injury as a modifiable therapeutic target for cardioprotection or neuroprotection in patients undergoing cardiopulmonary resuscitation. *Resuscitation* 2016; **105**: 85-91 [PMID: 27131843 DOI: 10.1016/j.resuscitation.2016.04.009]

37 **Erecinska M**, Thoresen M, Silver IA. Effects of hypothermia on energy metabolism in Mammalian central nervous system. *J Cereb Blood Flow Metab* 2003; **23**: 513-530 [PMID: 12771566 DOI: 10.1097/01.WCB.0000066287.21705.21]

38 **González-Ibarra FP**, Varon J, López-Meza EG. Therapeutic hypothermia: critical review of the molecular mechanisms of action. *Front Neurol* 2011; **2**: 4 [PMID: 21331282 DOI: 10.3389/fneur.2011.00004]

39 **Chi OZ**, Liu X, Weiss HR. Effects of mild hypothermia on blood-brain barrier disruption during isoflurane or pentobarbital anesthesia. *Anesthesiology* 2001; **95**: 933-938 [PMID: 11605935 DOI: 10.1097/00000542-200110000-00023]

40 **Schwab S**, Georgiadis D, Berrouschot J, Schellinger PD, Graffagnino C, Mayer SA. Feasibility and safety of moderate hypothermia after massive hemispheric infarction. *Stroke* 2001; **32**: 2033-2035 [PMID: 11546893]

41 **Seule MA**, Muroi C, Mink S, Yonekawa Y, Keller E. Therapeutic hypothermia in patients with aneurysmal subarachnoid hemorrhage, refractory intracranial hypertension, or cerebral vasospasm. *Neurosurgery* 2009; **64**: 86-93

42 **Park CK**, Jun SS, Kim MC, Kang JK. Effects of systemic hypothermia and selective brain cooling on ischemic brain damage and swelling. *Acta Neurochir Suppl* 1998; **71**: 225-228 [PMID: 9779191]

43 **Kawai N**, Nakamura T, Okauchi M, Nagao S. Effects of hypothermia on intracranial pressure and brain edema formation: studies in a rat acute subdural hematoma model. *J Neurotrauma* 2000; **17**: 193-202 [PMID: 10757325]

44 **Brott T**, Bogousslavsky J. Treatment of acute ischemic stroke. *N Engl J Med* 2000; **343**: 710-722 [PMID: 10974136 DOI: 10.1056/NEJM200009073431007]

45 **Suwannakin A**, Muengtaweepongsa S. Initial experience of therapeutic hypothermia after cardiac arrest with surface cooling method in Thammasat Chalerm Prakiat Hospital: two cases report. *J Med Assoc Thai* 2011; **94** Suppl 7: S190-S193 [PMID: 22619928]

46 **Pinichjindasup A**, Homvises B, Muengtaweepongsa S. Therapeutic hypothermia with extracorporeal membrane oxygenation (ECMO) and surface cooling in post-cardiac arrest patients: 4 case reports. *J Med Assoc Thai* 2014; **97** Suppl 8: S223-S227 [PMID: 25518319]

47 **Polderman KH**. Application of therapeutic hypothermia in the intensive care unit. Opportunities and pitfalls of a promising treatment modality--Part 2: Practical aspects and side effects. *Intensive Care Med* 2004; **30**: 757-769 [PMID: 14767590 DOI: 10.1007/s00134-003-2151-y]

48 **Polderman KH**, Rijnsburger ER, Peerdeman SM, Girbes AR. Induction of hypothermia in patients with various types of neurologic injury with use of large volumes of ice-cold intravenous fluid. *Crit Care Med* 2005; **33**: 2744-2751 [PMID: 16352954 DOI: 10.1097/2701.CCM.0000190427.0000188735.0000190419]

49 **Bernard S**, Buist M, Monteiro O, Smith K. Induced hypothermia using large volume, ice-cold intravenous fluid in comatose survivors of out-of-hospital cardiac arrest: a preliminary report. *Resuscitation* 2003; **56**: 9-13 [PMID: 12505732]

50 **Wang H**, Olivero W, Lanzino G, Elkins W, Rose J, Honings D, Rodde M, Burnham J, Wang D. Rapid and selective cerebral hypothermia achieved using a cooling helmet. *J Neurosurg* 2004; **100**: 272-277 [PMID: 15086235]

51 **Oh SH**, Oh JS, Kim YM, Park KN, Choi SP, Kim GW, Jeung KW, Jang TC, Park YS, Kyong YY. An observational study of surface versus endovascular cooling techniques in cardiac arrest patients: a propensity-matched analysis. *Crit Care* 2015; **19**: 85 [PMID: 25880667 DOI: 10.1186/s13054-015-0819-7]

52 **Glover GW**, Thomas RM, Vamvakas G, Al-Subaie N, Cranshaw J, Walden A, Wise MP, Ostermann M, Thomas-Jones E, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wetterslev J, Friberg H, Nielsen N. Intravascular versus surface cooling for targeted temperature management after out-of-hospital cardiac arrest - an analysis of the TTM trial data. *Crit Care* 2016; **20**: 381 [PMID: 27887653 DOI: 10.1186/s13054-016-1552-6]

53 **Al-Senani FM**, Graffagnino C, Grotta JC, Saiki R, Wood D, Chung W, Palmer G, Collins KA. A prospective, multicenter pilot study to evaluate the feasibility and safety of using the CoolGard System and Icy catheter following cardiac arrest. *Resuscitation* 2004; **62**: 143-150 [PMID: 15294399 DOI: 10.1016/j.resuscitation.2004.02.016]

54 **Lyden PD**, Allgren RL, Ng K, Akins P, Meyer B, Al-Sanani F, Lutsep H, Dobak J, Matsubara BS, Zivin J. Intravascular Cooling in the Treatment of Stroke (ICTuS): early clinical experience. *J Stroke Cerebrovasc Dis* 2005; **14**: 107-114 [PMID: 17904009 DOI: 10.1016/j.jstrokecerebrovasdis.2005.01.001]

55 **Choi HA**, Ko SB, Presciutti M, Fernandez L, Carpenter AM, Lesch C, Gilmore E, Malhotra R, Mayer SA, Lee K, Claassen J, Schmidt JM, Badjatia N. Prevention of shivering during therapeutic temperature modulation: the Columbia anti-shivering protocol. *Neurocrit Care* 2011; **14**: 389-394 [PMID: 21210305 DOI: 10.1007/s12028-010-9474-7]

56 **De Georgia MA**, Krieger DW, Abou-Chebl A, Devlin TG, Jauss M, Davis SM, Koroshetz WJ, Rordorf G, Warach S. Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. *Neurology* 2004; **63**: 312-317 [PMID: 15277626]

57 **Lyden PD**, Hemmen TM, Grotta J, Rapp K, Raman R. Endovascular therapeutic hypothermia for acute ischemic stroke: ICTuS 2/3 protocol. *Int J Stroke* 2014; **9**: 117-125 [PMID: 24206528 DOI: 10.1111/ijs.12151]

58 **Wolfe MM**, Boylan MO. Obesity and the gastrointestinal tract: you are what you eat. *J Clin Gastroenterol* 2014; **48**: 817-822 [PMID: 24828362]

59 **Krieger DW**, De Georgia MA, Abou-Chebl A, Andrefsky JC, Sila CA, Katzan IL, Mayberg MR, Furlan AJ. Cooling for acute ischemic brain damage (cool aid): an open pilot study of induced hypothermia in acute ischemic stroke. *Stroke* 2001; **32**: 1847-1854 [PMID: 11486115]

60 **Fischer M**, Lackner P, Beer R, Helbok R, Pfausler B, Schneider D, Schmutzhard E, Broessner G. Cooling Activity is Associated with Neurological Outcome in Patients with Severe Cerebrovascular Disease Undergoing Endovascular Temperature Control. *Neurocrit Care* 2015; **23**: 205-209 [PMID: 25693893 DOI: 10.1007/s12028-015-0122-0]

61 **Seder DB**, Van der Kloot TE. Methods of cooling: practical aspects of therapeutic temperature management. *Crit Care Med* 2009; **37**: S211-S222 [PMID: 19535949 DOI: 10.1097/CCM.0b013e3181aa5bad]

62 **Uray T**, Sterz F, Janata A, Wandaller C, Holzer M, Laggner AN, Behringer W. Surface cooling with a new cooling-blanket for rapid induction of mild hypothermia in humans after cardiac arrest: A feasibility trial. *Circulation* 2006; **114**: 1190-1190

63 **Dhaese HL**, Martens PR, Müller NH, Casier IM, Mulier JP, Heytens L. The use of emergency medical cooling system pads in the treatment of malignant hyperthermia. *Eur J Anaesthesiol* 2010; **27**: 83-85 [PMID: 19851114 DOI: 10.1097/EJA.0b013e328330404a]

64 **Hegazy A**, Lapierre D, Althenayan E. Targeted temperature management after cardiac arrest and fever control with an esophageal cooling device. *Critical Care* 2015; **19** (Suppl 1): P424 [DOI: 10.1186/cc14504]

65 CritiCool Specification M (Rehovot, Israel). 510K for CritiCool system. Available from: URL: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ID=DEN140018

66 **Arrica M**, Bissonnette B. Therapeutic hypothermia. *Semin Cardiothorac Vasc Anesth* 2007; **11**: 6-15 [PMID: 17484169 DOI: 10.1177/1089253206297409]

67 **Nair SU**, Lundbye JB. The occurrence of shivering in cardiac arrest survivors undergoing therapeutic hypothermia is associated with a good neurologic outcome. *Resuscitation* 2013; **84**: 626-629 [PMID: 23201502 DOI: 10.1016/j.resuscitation.2012.11.018]

68 **Presciutti M**, Bader MK, Hepburn M. Shivering management during therapeutic temperature modulation: nurses' perspective. *Crit Care Nurse* 2012; **32**: 33-42 [PMID: 22298716 DOI: 10.4037/ccn2012189]

69 **Logan A**, Sangkachand P, Funk M. Optimal management of shivering during therapeutic hypothermia after cardiac arrest. *Crit Care Nurse* 2011; **31**: e18-e30 [PMID: 22135340 DOI: 10.4037/ccn2011618]

70 **Clifton GL**, Miller ER, Choi SC, Levin HS, McCauley S, Smith KR, Muizelaar JP, Wagner FC, Marion DW, Luerssen TG, Chesnut RM, Schwartz M. Lack of effect of induction of hypothermia after acute brain injury. *N Engl J Med* 2001; **344**: 556-563 [PMID: 11207351]

71 **Thomsen JH**, Hassager C, Bro-Jeppesen J, Søholm H, Nielsen N, Wanscher M, Køber L, Pehrson S, Kjaergaard J. Sinus bradycardia during hypothermia in comatose survivors of out-of-hospital cardiac arrest - a new early marker of favorable outcome? *Resuscitation* 2015; **89**: 36-42 [PMID: 25619443 DOI: 10.1016/j.resuscitation.2014.12.031]

72 **Muengtaweepongsa S**, Jantanukul A, Suwanprasert K. Should the heart rate including the heart rate variability be important prognostigators in cardiac arrest? *Resuscitation* 2016; **98**: e15 [PMID: 26597105 DOI: 10.1016/j.resuscitation.2015.08.026]

73 **Srivilaithon W**, Muengtaweepongsa S. The Outcomes of Targeted Temperature Management After Cardiac Arrest at Emergency Department: A Real-World Experience in a Developing Country. *Ther Hypothermia Temp Manag* 2017; **7**: 24-29 [PMID: 27835072 DOI: 10.1089/ther.2016.0014]

74 **Varon J**, Acosta P. Therapeutic hypothermia: past, present, and future. *Chest* 2008; **133**: 1267-1274 [PMID: 18460529 DOI: 10.1378/chest.07-2190]

75 **Bernard SA**, Buist M. Induced hypothermia in critical care medicine: a review. *Crit Care Med* 2003; **31**: 2041-2051 [PMID: 12847402 DOI: 10.1097/01.CCM.0000069731.18472.61]

76 **Lehot JJ**, Piriz H, Villard J, Cohen R, Guidollet J. Glucose homeostasis. Comparison between hypothermic and normothermic cardiopulmonary bypass. *Chest* 1992; **102**: 106-111 [PMID: 1623737]

77 **Gagnon DJ**, Nielsen N, Fraser GL, Riker RR, Dziodzio J, Sunde K, Hovdenes J, Stammet P, Friberg H, Rubertsson S, Wanscher M, Seder DB. Prophylactic antibiotics are associated with a lower incidence of pneumonia in cardiac arrest survivors treated with targeted temperature management. *Resuscitation* 2015; **92**: 154-159 [PMID: 25680823 DOI: 10.1016/j.resuscitation.2015.01.035]

78 **Nolan JP**, Neumar RW, Adrie C, Aibiki M, Berg RA, Böttiger BW, Callaway C, Clark RS, Geocadin RG, Jauch EC, Kern KB, Laurent I, Longstreth WT, Merchant RM, Morley P, Morrison LJ, Nadkarni V, Peberdy MA, Rivers EP, Rodriguez-Nunez A, Sellke FW, Spaulding C, Sunde K, Hoek TV. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A Scientific Statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. *Resuscitation* 2008; **79**: 350-379 [PMID: 18963350 DOI: 10.1016/j.resuscitation.2008.09.017]

79 **Bro-Jeppesen J**, Kjaergaard J, Stammet P, Wise MP, Hovdenes J, Åneman A, Horn J, Devaux Y, Erlinge D, Gasche Y, Wanscher M, Cronberg T, Friberg H, Wetterslev J, Pellis T, Kuiper M, Nielsen N, Hassager C. Predictive value of interleukin-6 in post-cardiac arrest patients treated with targeted temperature management at 33 °C or 36 °C. *Resuscitation* 2016; **98**: 1-8 [PMID: 26525271 DOI: 10.1016/j.resuscitation.2015.10.009]

80 **Adrie C**, Laurent I, Monchi M, Cariou A, Dhainaou JF, Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? *Curr Opin Crit Care* 2004; **10**: 208-212 [PMID: 15166838]

81 **Adrie C**, Adib-Conquy M, Laurent I, Monchi M, Vinsonneau C, Fitting C, Fraisse F, Dinh-Xuan AT, Carli P, Spaulding C, Dhainaut JF, Cavaillon JM. Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. *Circulation* 2002; **106**: 562-568 [PMID: 12147537]

82 **Laver S**, Farrow C, Turner D, Nolan J. Mode of death after admission to an intensive care unit following cardiac arrest. *Intensive Care Med* 2004; **30**: 2126-2128 [PMID: 15365608 DOI: 10.1007/s00134-004-2425-z]

83 **Gunn AJ**, Thoresen M. Hypothermic neuroprotection. *NeuroRx* 2006; **3**: 154-169 [PMID: 16554254 DOI: 10.1016/j.nurx.2006.01.007]

84 **Holzer M**, Bernard SA, Hachimi-Idrissi S, Roine RO, Sterz F, Müllner M. Hypothermia for neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis. *Crit Care Med* 2005; **33**: 414-418 [PMID: 15699847]

85 **Froehler MT**, Geocadin RG. Hypothermia for neuroprotection after cardiac arrest: mechanisms, clinical trials and patient care. *J Neurol Sci* 2007; **261**: 118-126 [PMID: 17559883 DOI: 10.1016/j.jns.2007.04.042]

86 **Arrich J**, Holzer M, Herkner H, Müllner M. Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. *Cochrane Database Syst Rev* 2009; **(4)**: CD004128 [PMID: 19821320 DOI: 10.1002/14651858.CD004128.pub2]

87 **Nielsen N**, Wetterslev J, al-Subaie N, Andersson B, Bro-Jeppesen J, Bishop G, Brunetti I, Cranshaw J, Cronberg T, Edqvist K, Erlinge D, Gasche Y, Glover G, Hassager C, Horn J, Hovdenes J, Johnsson J, Kjaergaard J, Kuiper M, Langørgen J, Macken L, Martinell L, Martner P, Pellis T, Pelosi P, Petersen P, Persson S, Rundgren M, Saxena M, Svensson R, Stammet P, Thorén A, Undén J, Walden A, Wallskog J, Wanscher M, Wise MP, Wyon N, Aneman A, Friberg H. Target Temperature Management after out-of-hospital cardiac arrest--a randomized, parallel-group, assessor-blinded clinical trial--rationale and design. *Am Heart J* 2012; **163**: 541-548 [PMID: 22520518 DOI: 10.1016/j.ahj.2012.01.013]

88 **Nielsen N**, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Køber L, Langørgen J, Lilja G, Møller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H. Targeted temperature management at 33°C versus 36°C after cardiac arrest. *N Engl J Med* 2013; **369**: 2197-2206 [PMID: 24237006 DOI: 10.1056/NEJMoa1310519]

89 **Cronberg T**, Lilja G, Horn J, Kjaergaard J, Wise MP, Pellis T, Hovdenes J, Gasche Y, Åneman A, Stammet P, Erlinge D, Friberg H, Hassager C, Kuiper M, Wanscher M, Bosch F, Cranshaw J, Kleger GR, Persson S, Undén J, Walden A, Winkel P, Wetterslev J, Nielsen N. Neurologic Function and Health-Related Quality of Life in Patients Following Targeted Temperature Management at 33°C vs 36°C After Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. *JAMA Neurol* 2015; **72**: 634-641 [PMID: 25844993 DOI: 10.1001/jamaneurol.2015.0169]

90 **Dumas F**, Grimaldi D, Zuber B, Fichet J, Charpentier J, Pène F, Vivien B, Varenne O, Carli P, Jouven X, Empana JP, Cariou A. Is hypothermia after cardiac arrest effective in both shockable and nonshockable patients?: insights from a large registry. *Circulation* 2011; **123**: 877-886 [PMID: 21321156 DOI: 10.1161/CIRCULATIONAHA.110.987347]

91 **Hessel EA**. Therapeutic hypothermia after in-hospital cardiac arrest: a critique. *J Cardiothorac Vasc Anesth* 2014; **28**: 789-799 [PMID: 24751488 DOI: 10.1053/j.jvca.2014.01.015]

92 **Oddo M**, Ribordy V, Feihl F, Rossetti AO, Schaller MD, Chioléro R, Liaudet L. Early predictors of outcome in comatose survivors of ventricular fibrillation and non-ventricular fibrillation cardiac arrest treated with hypothermia: a prospective study. *Crit Care Med* 2008; **36**: 2296-2301 [PMID: 18664785 DOI: 10.1097/CCM.0b013e3181802599]

93 **Chan PS**, Berg RA, Tang Y, Curtis LH, Spertus JA. Association Between Therapeutic Hypothermia and Survival After In-Hospital Cardiac Arrest. *JAMA* 2016; **316**: 1375-1382 [PMID: 27701659 DOI: 10.1001/jama.2016.14380]

94 **Arrich J**, Holzer M, Havel C, Müllner M, Herkner H. Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. *Cochrane Database Syst Rev* 2016; **2**: CD004128 [PMID: 26878327 DOI: 10.1002/14651858.CD004128.pub4]

95 **Moler FW**, Silverstein FS, Meert KL, Clark AE, Holubkov R, Browning B, Slomine BS, Christensen JR, Dean JM. Rationale, timeline, study design, and protocol overview of the therapeutic hypothermia after pediatric cardiac arrest trials. *Pediatr Crit Care Med* 2013; **14**: e304-e315 [PMID: 23842585 DOI: 10.1097/PCC.0b013e31828a863a]

96 **Moler FW**, Silverstein FS, Holubkov R, Slomine BS, Christensen JR, Nadkarni VM, Meert KL, Clark AE, Browning B, Pemberton VL, Page K, Shankaran S, Hutchison JS, Newth CJ, Bennett KS, Berger JT, Topjian A, Pineda JA, Koch JD, Schleien CL, Dalton HJ, Ofori-Amanfo G, Goodman DM, Fink EL, McQuillen P, Zimmerman JJ, Thomas NJ, van der Jagt EW, Porter MB, Meyer MT, Harrison R, Pham N, Schwarz AJ, Nowak JE, Alten J, Wheeler DS, Bhalala US, Lidsky K, Lloyd E, Mathur M, Shah S, Wu T, Theodorou AA, Sanders RC, Dean JM. Therapeutic hypothermia after out-of-hospital cardiac arrest in children. *N Engl J Med* 2015; **372**: 1898-1908 [PMID: 25913022 DOI: 10.1056/NEJMoa1411480]

97 **Moler FW**, Silverstein FS, Holubkov R, Slomine BS, Christensen JR, Nadkarni VM, Meert KL, Browning B, Pemberton VL, Page K, Gildea MR, Scholefield BR, Shankaran S, Hutchison JS, Berger JT, Ofori-Amanfo G, Newth CJ, Topjian A, Bennett KS, Koch JD, Pham N, Chanani NK, Pineda JA, Harrison R, Dalton HJ, Alten J, Schleien CL, Goodman DM, Zimmerman JJ, Bhalala US, Schwarz AJ, Porter MB, Shah S, Fink EL, McQuillen P, Wu T, Skellett S, Thomas NJ, Nowak JE, Baines PB, Pappachan J, Mathur M, Lloyd E, van der Jagt EW, Dobyns EL, Meyer MT, Sanders RC, Clark AE, Dean JM. Therapeutic Hypothermia after In-Hospital Cardiac Arrest in Children. *N Engl J Med* 2017; **376**: 318-329 [PMID: 28118559 DOI: 10.1056/NEJMoa1610493]

98 **van der Worp HB**, Sena ES, Donnan GA, Howells DW, Macleod MR. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. *Brain* 2007; **130**: 3063-3074 [PMID: 17478443]

99 **van der Worp HB**, Macleod MR, Kollmar R. Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? *J Cereb Blood Flow Metab* 2010; **30**: 1079-1093 [PMID: 20354545 DOI: 10.1038/jcbfm.2010.44]

100 **Hemmen TM**, Raman R, Guluma KZ, Meyer BC, Gomes JA, Cruz-Flores S, Wijman CA, Rapp KS, Grotta JC, Lyden PD. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. *Stroke* 2010; **41**: 2265-2270 [PMID: 20724711 DOI: 10.1161/strokeaha.110.592295]

101 **Lyden P**, Hemmen T, Grotta J, Rapp K, Ernstrom K, Rzesiewicz T, Parker S, Concha M, Hussain S, Agarwal S, Meyer B, Jurf J, Altafullah I, Raman R. Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). *Stroke* 2016; **47**: 2888-2895 [PMID: 27834742 DOI: 10.1161/STROKEAHA.116.014200]

102 **Tang XN**, Liu L, Koike MA, Yenari MA. Mild hypothermia reduces tissue plasminogen activator-related hemorrhage and blood brain barrier disruption after experimental stroke. *Ther Hypothermia Temp Manag* 2013; **3**: 74-83 [PMID: 23781399]

103 **Hong JM**, Lee JS, Song HJ, Jeong HS, Choi HA, Lee K. Therapeutic hypothermia after recanalization in patients with acute ischemic stroke. *Stroke* 2014; **45**: 134-140 [PMID: 24203846 DOI: 10.1161/STROKEAHA.113.003143]

104 **van der Worp HB**, Macleod MR, Bath PM, Demotes J, Durand-Zaleski I, Gebhardt B, Gluud C, Kollmar R, Krieger DW, Lees KR, Molina C, Montaner J, Roine RO, Petersson J, Staykov D, Szabo I, Wardlaw JM, Schwab S. EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke. *Int J Stroke* 2014; **9**: 642-645 [PMID: 24828363 DOI: 10.1111/ijs.12294]

105 **Jauch EC**, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2013; **44**: 870-947 [PMID: 23370205]

106 **Wijdicks EF**, Sheth KN, Carter BS, Greer DM, Kasner SE, Kimberly WT, Schwab S, Smith EE, Tamargo RJ, Wintermark M. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014; **45**: 1222-1238 [PMID: 24481970 DOI: 10.1161/01.str.0000441965.15164.d6]

107 **Murtha LA**, McLeod DD, Pepperall D, McCann SK, Beard DJ, Tomkins AJ, Holmes WM, McCabe C, Macrae IM, Spratt NJ. Intracranial pressure elevation after ischemic stroke in rats: cerebral edema is not the only cause, and short-duration mild hypothermia is a highly effective preventive therapy. *J Cereb Blood Flow Metab* 2015; **35**: 592-600 [PMID: 25515213 DOI: 10.1038/jcbfm.2014.230]

108 **Dietrich WD**, Alonso O, Busto R, Globus MY, Ginsberg MD. Post-traumatic brain hypothermia reduces histopathological damage following concussive brain injury in the rat. *Acta Neuropathol* 1994; **87**: 250-258 [PMID: 8009957]

109 **Jiang JY**, Lyeth BG, Kapasi MZ, Jenkins LW, Povlishock JT. Moderate hypothermia reduces blood-brain barrier disruption following traumatic brain injury in the rat. *Acta Neuropathol* 1992; **84**: 495-500 [PMID: 1462764]

110 **Gu X**, Wei ZZ, Espinera A, Lee JH, Ji X, Wei L, Dix TA, Yu SP. Pharmacologically induced hypothermia attenuates traumatic brain injury in neonatal rats. *Exp Neurol* 2015; **267**: 135-142 [PMID: 25725354 DOI: 10.1016/j.expneurol.2015.02.029]

111 **Zhi D**, Zhang S, Lin X. Study on therapeutic mechanism and clinical effect of mild hypothermia in patients with severe head injury. *Surg Neurol* 2003; **59**: 381-385 [PMID: 12765810]

112 **Jiang J**, Yu M, Zhu C. Effect of long-term mild hypothermia therapy in patients with severe traumatic brain injury: 1-year follow-up review of 87 cases. *J Neurosurg* 2000; **93**: 546-549 [PMID: 11014530 DOI: 10.3171/jns.2000.93.4.0546]

113 **Henderson WR**, Dhingra VK, Chittock DR, Fenwick JC, Ronco JJ. Hypothermia in the management of traumatic brain injury. A systematic review and meta-analysis. *Intensive Care Med* 2003; **29**: 1637-1644 [PMID: 12915937 DOI: 10.1007/s00134-003-1848-2]

114 **Peterson K**, Carson S, Carney N. Hypothermia treatment for traumatic brain injury: a systematic review and meta-analysis. *J Neurotrauma* 2008; **25**: 62-71 [PMID: 18355159 DOI: 10.1089/neu.2007.0424]

115 **McIntyre LA**, Fergusson DA, Hébert PC, Moher D, Hutchison JS. Prolonged therapeutic hypothermia after traumatic brain injury in adults: a systematic review. *JAMA* 2003; **289**: 2992-2999 [PMID: 12799408 DOI: 10.1001/jama.289.22.2992]

116 **Hutchison JS**, Ward RE, Lacroix J, Hébert PC, Barnes MA, Bohn DJ, Dirks PB, Doucette S, Fergusson D, Gottesman R, Joffe AR, Kirpalani HM, Meyer PG, Morris KP, Moher D, Singh RN, Skippen PW. Hypothermia therapy after traumatic brain injury in children. *N Engl J Med* 2008; **358**: 2447-2456 [PMID: 18525042]

117 **Clifton GL**, Valadka A, Zygun D, Coffey CS, Drever P, Fourwinds S, Janis LS, Wilde E, Taylor P, Harshman K, Conley A, Puccio A, Levin HS, McCauley SR, Bucholz RD, Smith KR, Schmidt JH, Scott JN, Yonas H, Okonkwo DO. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial. *Lancet Neurol* 2011; **10**: 131-139 [PMID: 21169065]

118 **Ghajar J**. Traumatic brain injury. *Lancet* 2000; **356**: 923-929 [PMID: 11036909]

119 **Ducrocq SC**, Meyer PG, Orliaguet GA, Blanot S, Laurent-Vannier A, Renier D, Carli PA. Epidemiology and early predictive factors of mortality and outcome in children with traumatic severe brain injury: experience of a French pediatric trauma center. *Pediatr Crit Care Med* 2006; **7**: 461-467 [PMID: 16885795 DOI: 10.1097/01.PCC.0000235245.49129.27]

120 **Wijayatilake DS**, Shepherd SJ, Sherren PB. Updates in the management of intracranial pressure in traumatic brain injury. *Curr Opin Anaesthesiol* 2012; **25**: 540-547 [PMID: 22914351 DOI: 10.1097/ACO.0b013e328357960a]

121 **Sinclair HL**, Andrews PJ. Bench-to-bedside review: Hypothermia in traumatic brain injury. *Crit Care* 2010; **14**: 204 [PMID: 20236503 DOI: 10.1186/cc8220]

122 **Lei J**, Gao G, Mao Q, Feng J, Wang L, You W, Jiang J. Rationale, methodology, and implementation of a nationwide multicenter randomized controlled trial of long-term mild hypothermia for severe traumatic brain injury (the LTH-1 trial). *Contemp Clin Trials* 2015; **40**: 9-14 [PMID: 25460339 DOI: 10.1016/j.cct.2014.11.008]

123 **Andrews PJ**, Sinclair HL, Rodriguez A, Harris BA, Battison CG, Rhodes JK, Murray GD. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. *N Engl J Med* 2015; **373**: 2403-2412 [PMID: 26444221 DOI: 10.1056/NEJMoa1507581]

124 **Zhu Y**, Yin H, Zhang R, Ye X, Wei J. Therapeutic hypothermia versus normothermia in adult patients with traumatic brain injury: a meta-analysis. *Springerplus* 2016; **5**: 801 [PMID: 27390642 DOI: 10.1186/s40064-016-2391-2]

125 **Ahmad FU**, Starke RM, Komotar RJ, Connolly ES. A Randomized Clinical Trial of Hypothermia as a Preferred Second-Line Treatment for Elevated Intracranial Pressure After Traumatic Brain Injury. *Neurosurgery* 2016; **78**: N10-N11 [PMID: 26779789 DOI: 10.1227/NEU.0000000000001171]

126 **Yokobori S**, Yokota H. Targeted temperature management in traumatic brain injury. *J Intensive Care* 2016; **4**: 28 [PMID: 27123304 DOI: 10.1186/s40560-016-0137-4]

127 **Rehman T**, Deboisblanc BP. Persistent fever in the ICU. *Chest* 2014; **145**: 158-165 [PMID: 24394828 DOI: 10.1378/chest.12-2843]

128 **Diringer MN**, Reaven NL, Funk SE, Uman GC. Elevated body temperature independently contributes to increased length of stay in neurologic intensive care unit patients. *Crit Care Med* 2004; **32**: 1489-1495 [PMID: 15241093 DOI: 10.1097/01.ccm.0000129484.61912.84]

129 **Olsen TS**, Weber UJ, Kammersgaard LP. Therapeutic hypothermia for acute stroke. *Lancet Neurol* 2003; **2**: 410-416 [PMID: 12849119]

130 **Niven DJ**, Laupland KB. Pyrexia: aetiology in the ICU. *Crit Care* 2016; **20**: 247 [PMID: 27581757 DOI: 10.1186/s13054-016-1406-2]

131 **Diringer MN**. Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system. *Crit Care Med* 2004; **32**: 559-564 [PMID: 14758179 DOI: 10.1097/01.ccm.0000108868.97433.3f]

132 **Mayer SA**, Kowalski RG, Presciutti M, Ostapkovich ND, McGann E, Fitzsimmons BF, Yavagal DR, Du YE, Naidech AM, Janjua NA, Claassen J, Kreiter KT, Parra A, Commichau C. Clinical trial of a novel surface cooling system for fever control in neurocritical care patients. *Crit Care Med* 2004; **32**: 2508-2515 [PMID: 15599159]

133 **Schortgen F**, Clabault K, Katsahian S, Devaquet J, Mercat A, Deye N, Dellamonica J, Bouadma L, Cook F, Beji O, Brun-Buisson C, Lemaire F, Brochard L. Fever control using external cooling in septic shock: a randomized controlled trial. *Am J Respir Crit Care Med* 2012; **185**: 1088-1095 [PMID: 22366046 DOI: 10.1164/rccm.201110-1820OC]

134 **Zhang Z**. Antipyretic therapy in critically ill patients with established sepsis: a trial sequential analysis. *PLoS One* 2015; **10**: e0117279 [PMID: 25710375 DOI: 10.1371/journal.pone.0117279]

135 **Zhang Z**, Chen L, Ni H. Antipyretic therapy in critically ill patients with sepsis: an interaction with body temperature. *PLoS One* 2015; **10**: e0121919 [PMID: 25822614 DOI: 10.1371/journal.pone.0121919]

136 **BIGELOW WG**, CALLAGHAN JC, HOPPS JA. General hypothermia for experimental intracardiac surgery; the use of electrophrenic respirations, an artificial pacemaker for cardiac standstill, and radio-frequency rewarming in general hypothermia. *Trans Meet Am Surg Assoc Am Surg Assoc* 1950; **68**: 211-219 [PMID: 14788154]

137 **Bigelow WC**. Methods for inducing hypothermia and rewarming. *Ann N Y Acad Sci* 1959; **80**: 522-532 [PMID: 13800633]

138 **Todd MM**, Hindman BJ, Clarke WR, Torner JC. Mild intraoperative hypothermia during surgery for intracranial aneurysm. *N Engl J Med* 2005; **352**: 135-145 [PMID: 15647576 DOI: 10.1056/NEJMoa040975]

139 **MacLellan CL**, Girgis J, Colbourne F. Delayed onset of prolonged hypothermia improves outcome after intracerebral hemorrhage in rats. *J Cereb Blood Flow Metab* 2004; **24**: 432-440 [PMID: 15087712 DOI: 10.1097/00004647-200404000-00008]

140 **Rincon F**, Friedman DP, Bell R, Mayer SA, Bray PF. Targeted temperature management after intracerebral hemorrhage (TTM-ICH): methodology of a prospective randomized clinical trial. *Int J Stroke* 2014; **9**: 646-651 [PMID: 24450819 DOI: 10.1111/ijs.12220]

141 **Lopez GA**. Temperature Management in the Neurointensive Care Unit. *Curr Treat Options Neurol* 2016; **18**: 12 [PMID: 26920417 DOI: 10.1007/s11940-016-0393-6]

142 **Hansebout RR**, Hansebout CR. Local cooling for traumatic spinal cord injury: outcomes in 20 patients and review of the literature. *J Neurosurg Spine* 2014; **20**: 550-561 [PMID: 24628130 DOI: 10.3171/2014.2.SPINE13318]

143 **Neuberger J**. Management of the Patient with Fulminant Hepatic Failure Awaiting Liver Transplantation. Liver Transplantation: John Wiley & Sons, Ltd, 2013: 93-100

144 **Niemann CU**, Feiner J, Swain S, Bunting S, Friedman M, Crutchfield M, Broglio K, Hirose R, Roberts JP, Malinoski D. Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function. *N Engl J Med* 2015; **373**: 405-414 [PMID: 26222557 DOI: 10.1056/NEJMoa1501969]

145 **Jochmans I**, Watson CJ. Taking the Heat Out of Organ Donation. *N Engl J Med* 2015; **373**: 477-478 [PMID: 26222564 DOI: 10.1056/NEJMe1507573]

**P-Reviewer:** Bugaj AM, Maric I, Sip M, Zhang Z **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Medical laboratory technology

**Country of origin:** Thailand

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

****

**Figure 1 Hypoxic/ischemic cascade[44] (modified from ref. [44], use with permission).**

**Figure 2 Temperature record of a patient with post-cardiac arrest with targeted temperature management.**



**Figure 3 A patient is undergoing targeted temperature management with cold water pads.**

|  |  |
| --- | --- |
| Table 1 Bedside Shivering Assessment Score[69] | |
| 0 | No shivering |
| 1 | Mild: Shivering confines to cervical and/or thorax only |
| 2 | Moderate: Shivering extends to whole movement of upper limbs |
| 3 | Severe: Shivering spreads to overall movement of trunk, upper limbs and lower limbs |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  | | --- | --- | --- | |  | Australian trial | European trial | | Sample size | *n* = 77 | *n* = 275 | | TTM *vs* untreated | 43 TTM *vs*  34 untreated | 137 TTM *vs*  138 untreated | | Initial rhythm | VT/VF | VT/VF | | Method of TTM | Surface with ice packs | Surface with cooling blankets/pads and ice packs | | Place of initiation | Emergency department | Prehospital setting | | Target temperature | 33 degrees Celsius | 32-34 degrees Celsius | | Duration of TTM | 12 h | 24 h | | Time of Follow up | 30 d | 6 mo | | Outcomes | NNT of 7 to avoid death | NNT of 6 to improve neurological outcomes |   **Table 2 Summary of the landmark randomized control trials for targeted temperature management in post-cardiac arrest syndrome** |

TTM: Targeted temperature management; VF: Ventricular fibrillation; VT: Ventricular tachycardia; NNT: Number-needed-to-treat.

|  |
| --- |
| Table 3 Inclusion and exclusion criteria for targeted temperature management after cardiac arrest at Thammasat University Hospital |
| Inclusion criteria  Witnessed arrest  Any initial rhythm, However initial rhythm VF or pulseless VT is the first priority  Time to ACLS was less than 15 min and total of ACLS time less than 60 min  GCS of 8 or below  SBP of > 90 with or without vasopressors  Less than 8 h have elapsed since return of spontaneous circulation (ROSC) |
| Exclusion criteria  Pregnancy  Known functional dependence  Down time of > 30 min  ACLS preformed for > 60 min  Known terminal illness  Comatose state prior to cardiac arrest  Prolonged hypotension (*i.e*., MAP < 60 for >30 min)  Evidence of hypoxemia for > 15 min following ROSC  Known coagulopathy that cannot be reversed |

VF: Ventricular fibrillation; VT: Ventricular tachycardia; ROSC: Restored of systemic circulation.